Physician profile
Charles Buzzanell
NPI 1841364551
$8,692.53
in general payments reported to CMS, 2019-2025
44 companies · $2,736 in 2025
The $2,736 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $504 · 2021: $887 · 2022: $1,009 · 2023: $1,277 · 2024: $1,739 · 2025: $2,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059 · Travel and Lodging: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,059.34 |
| Travel and Lodging | $692.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,510.16 | 2020-2024 | Senza |
| Curonix LLC | $711.23 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $643.19 | 2019-2025 | Relistor, Trulance |
| Abbvie INC. | $623.36 | 2019-2025 | Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $538.44 | 2019-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $474.89 | 2022-2025 | Inceptiv, Intellis Adaptivestim, Vanta Adaptivestim |
| Globus Medical, INC. | $466.67 | 2025 | Senza |
| Forte Bio-Pharma LLC | $438.63 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Teva Pharmaceuticals USA, INC. | $358.79 | 2019-2025 | Ajovy, Austedo Xr |
| Scilex Pharmaceuticals INC. | $311.57 | 2021-2024 | Ztlido |
| Pfizer INC. | $274.67 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $234.68 | 2020-2021 | |
| Lilly USA, LLC | $230.03 | 2019-2024 | Emgality, Reyvow |
| Uswm, LLC | $208.05 | 2021-2024 | Lucemyra, Zimhi |
| Vertex Pharmaceuticals Incorporated | $170.43 | 2024-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Buzzanell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.